ProclaRx Hosts Awareness and Networking Event to Promote the Breakthrough Medical Discovery

WOODMERE, Ohio, Dec. 9, 2016 /PRNewswire/ -- On Tuesday, November 29, 2016, ProclaRx, a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections, held an awareness and networking event to promote its breakthrough medical discovery.

Logo - http://photos.prnewswire.com/prnh/20161208/447250LOGO

The evening event was hosted at CFBank in Woodmere, Ohio. ProclaRx CEO, Dr. Joseph D. Kittle, Jr., gave a presentation demonstrating how the ProclaRx antibody technology disrupts bacterial biofilms to solve the major clinical and public health problem related to recurrent infections and antibiotic resistance. Other featured presenters and notable attendees included: Bob Milbourne, President of RHM Advisors; George K. Richards, President of Capital Drugs; Lee Fisher, former Ohio Lt. Governor; and Matthew McFarland, Director of Technology Commercialization at Nationwide Children's Hospital.

"It was wonderful to see the strong support and interest from the Cleveland community," said Nick Henderson, Chairman, ProclaRx. "Antibiotic resistance is a growing public health concern worldwide and we believe the ProclaRx technology provides the solution to many of these issues.  The outpouring of support ProclaRx received at the Cleveland event will go a long way towards rapidly getting our solutions in the hands of the clinicians – where it can start benefitting all those suffering from biofilm-related bacterial infections."

ProclaRx's technology is envisioned to address unmet needs in patients suffering from not only ear infections, but also chronic sinusitis. The treatment is intended to disrupt and clear bacterial biofilm infections.

Established in 2014, ProclaRx and its staff of experienced scientists are committed to eliminating the causes of countless chronic and recurrent human infections. The Ohio-based company prides itself on developing and commercializing anti-infective technologies, with the goal of eliminating biofilms and helping cure diseases. With $6.5 million invested to-date, ProclaRx is seeking additional strategic partners to help further its continued efforts to develop multiple innovative therapeutics for patients suffering from serious bacterial infections.

To learn more about ProclaRx, please visit www.proclarx.com. If you are interested in supporting ProclaRx's efforts, please contact Doug Martin for more information at [email protected].

About ProclaRx:
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, chronic suppurative otitis media, and CVID sinusitis. Visit www.proclarx.com, call 949-302-2165, or email [email protected].

Media Contacts:
Courtney Megaughey
Public Relations & Marketing Coordinator CSSi
(443) 308-5831
[email protected]

SOURCE ProclaRx

Related Links

http://www.proclarx.com